2024-10-01 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis

### 1. Performance Comparison

Amgen Inc. (AMGN) has delivered a cumulative return of 83.64%, lagging behind the S&P 500 (VOO) which has returned 133.28%. This translates to a current relative divergence of -49.64%, meaning AMGN's performance has been below the S&P 500 for the past period, sitting at the 36.28% percentile of its historical divergence range. 

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops and manufactures a wide range of therapies for serious illnesses.

### 2. Recent Price Movement

* **Closing Price:** $327.7
* **5-day Moving Average:** $325.69
* **20-day Moving Average:** $329.47
* **60-day Moving Average:** $328.14

The stock is currently trading slightly above its 5-day and 60-day moving averages but below its 20-day moving average, indicating a potential trend reversal.

### 3. Technical Indicators

* **RSI:** 51.56 -  The RSI suggests that AMGN is neither overbought nor oversold.
* **PPO:** -0.38 -  The PPO indicates a slight bearish momentum, potentially suggesting a continuation of the recent price decline.
* **Delta_Previous_Relative_Divergence:** -6.98 - This negative value indicates a short-term downtrend, potentially reinforcing the bearish signal from the PPO.
* **Expected_Return:** 0.0% - This indicates a maximum potential 5-year return of 0% on current investments, indicating a potentially low-growth scenario for the stock.

### 4. Recent Earnings and Outlook

**Earnings:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |

**Analysis:** The most recent earnings release showed a strong performance with EPS exceeding expectations. However, the previous quarter showed a loss, indicating potential volatility. This quarter's earnings need to be evaluated in conjunction with the company's long-term growth strategy and market competition.

### 5. News and Recent Issues

**Recent Market Outlook:** AMGN has experienced price fluctuations recently, reflecting concerns about potential future growth and competition in the biotechnology sector.

**Analyst Opinions:** Analyst sentiment is mixed. Some analysts see potential for growth due to AMGN's strong product pipeline and market position. Others are cautious about potential pricing pressure and competition. 

**Performance Highlights:** AMGN continues to invest in research and development, focusing on innovative therapies. The company's commitment to innovation could drive future growth. However, the company faces challenges in managing costs and ensuring long-term sustainability.

### 6. Summary

AMGN has underperformed the S&P 500 in recent years, but its latest earnings report showed a strong performance. However, concerns about future growth and competition in the biotechnology sector are impacting the stock's performance. Technical indicators suggest a potential downtrend, although the RSI suggests a neutral sentiment. Overall, the outlook for AMGN is uncertain, with both potential for growth and risks to consider.

### 7. Conclusion

Amgen Inc. (AMGN) presents a mixed picture for investors. While the company shows strong financials and a robust pipeline, concerns about future growth and competition in the biotechnology sector remain. Technical indicators suggest a potential downtrend, but the company's commitment to innovation and its existing market position provide opportunities for future growth. It is crucial for investors to carefully consider the company's long-term strategy, market conditions, and potential risks before making investment decisions. 
